Health Canada approves first-ever gene replacement therapy, Luxturna®

Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Luxturna® (voretigene neparvovec), a one-time gene therapy for the treatment of adult and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells. The presence of biallelic RPE65 mutations should be confirmed by an accredited laboratory using validated assay methods.

NewsGuest UserOctober 15, 2020Novartis, Gene therapy, Approbation, Health Canada